Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry
Authors:
- Raymond W. HughleyRHRaymond W. Hughley
- Marco MatejcicMMMarco Matejcic
- Ziwei SongZSZiwei Song
- Xin ShengXSXin Sheng
- Peggy WanPWPeggy Wan
- Lucy XiaLXLucy Xia
- Steven N. HartSHSteven N. Hart
- Chunling HuCHChunling Hu
- Siddhartha YadavSYSiddhartha Yadav
- Alexander LubmawaALAlexander Lubmawa
- Vicky KidduVKVicky Kiddu
- Frank AsiimweFAFrank Asiimwe
Open Access
- 14 December 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (12) , 2544-2550
Abstract
Prostate cancer risk is influenced by rare and common germline variants. We examined the aggregate association of rare germline pathogenic/likely pathogenic/deleterious (P/LP/D) variants in ATM, BRCA2, PALB2, and NBN with a polygenic risk score (PRS) on prostate cancer risk among 1,796 prostate cancer cases (222 metastatic) and 1,424 controls of African ancestry. Relative to P/LP/D non-carriers at average genetic risk (33%–66% of PRS), men with low (0%–33%) and high (66%–100%) PRS had Odds Ratios (ORs) for overall prostate cancer of 2.08 [95% confidence interval (CI) = 0.58–7.49] and 18.06 (95% CI = 4.24–76.84) among P/LP/D carriers and 0.57 (95% CI = 0.46–0.71) and 3.02 (95% CI = 2.53–3.60) among non-carriers, respectively. The OR for metastatic prostate cancer was 2.73 (95% CI = 0.24–30.54) and 28.99 (95% CI = 4.39–191.43) among P/LP/D carriers and 0.54 (95% CI = 0.31–0.95) and 3.22 (95% CI = 2.20–4.73) among non-carriers, for men with low and high PRS, respectively. Lifetime absolute risks of overall prostate cancer increased with PRS (low to high) from 9.8% to 51.5% in P/LP/D carriers and 5.5% to 23.9% in non-carriers. Lifetime absolute risks of metastatic prostate cancer increased with PRS from 1.9% to 18.1% in P/LP/D carriers and 0.3% to 2.2% in non-carriers These findings suggest that assessment of prostate cancer risk for rare variant carriers should include PRS status. Significance: These findings highlight the importance of considering rare and common variants to comprehensively assess prostate cancer risk in men of African ancestry.Keywords
All Related Versions
Funding Information
- HHS | NIH | National Cancer Institute (R01CA257328,U19 CA214253,U01CA164973,R01 CA165862,R35CA253187,R00CA246063)
- California Breast Cancer Research Program (99-00524V-10258)
- Prostate Cancer Foundation (20CHAS03 21YOUN11)
This publication has 28 references indexed in Scilit:
- ClinVar: public archive of interpretations of clinically relevant variantsNucleic Acids Research, 2015
- dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVsHuman Mutation, 2015
- A global reference for human genetic variationNature, 2015
- CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical settingGenome Medicine, 2015
- Prevalence of theHOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomesAnnals of Oncology, 2015
- A polygenic burden of rare disruptive mutations in schizophreniaNature, 2014
- A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer RiskEuropean Urology, 2014
- Prostate cancer in African-American men and polymorphism in the calcium-sensing receptorCancer Biology & Therapy, 2010
- Clinical Efficacy of Bone Alkaline Phosphatase and Prostate Specific Antigen in the Diagnosis of Bone Metastasis in Prostate CancerJournal of Urology, 1996
- A reappraisal of serial isotope bone scans in prostate cancerBritish Journal of Radiology, 1993